Showing 1661-1670 of 2042 results for "".
- Study Covering 2,000 Patients Over 10 Years Using ForeseeHome AMD Remote Monitoring Shows Better Outcomes for Patientshttps://modernod.com/news/study-covering-2000-patients-over-10-years-using-foreseehome-amd-remote-monitoring-shows-better-outcomes-for-patients/2480802/
- Heru Appoints Former Amazon Executive Brandon Barber as Chief Marketing Officerhttps://modernod.com/news/heru-appoints-former-amazon-executive-brandon-barber-as-chief-marketing-officer/2480679/Heru has announced that veteran tech industry executive Brandon Barber has joined the company as Chief Marketing Officer, effective February 14. “Brandon is a proven strategic and tactical leader whose depth of experience will greatly benefit Heru as we continue to red
- Nicox’s Positive Post Hoc Results from NCX 4251 Phase 2b Mississippi Trial Suggest Path Forward in Dry Eye Diseasehttps://modernod.com/news/nicoxs-positive-post-hoc-results-from-ncx-4251-phase-2b-mississippi-trial-suggest-path-forward-in-dry-eye-disease/2480480/Nicox SA announced positive post hoc results from its Mississippi Phase 2b clinical trial suggesting that once-daily dosed NCX 4251, fluticasone propionate ophth
- Ocutrx Technologies Receives Three Patents On Near-eye Pupil-forming Catadioptric Optical Enginehttps://modernod.com/news/ocutrx-technologies-receives-three-patents-on-near-eye-pupil-forming-catadioptric-optical-engine/2480469/Ocutrx Tec
- Harrow Health Granted Two Patents for Novel Surgical Dilation Formulationhttps://modernod.com/news/harrow-health-granted-two-patents-for-novel-surgical-dilation-formulation/2479377/Harrow Health announced that the United States Patent and Trademark Office issued two patents, entitled “Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof.” Harrow Health’s wholly owned subsidiary, ImprimisRx, provides surgical dilation (
- Shamir and Alpine F1 Team Form Partnershiphttps://modernod.com/news/shamir-and-alpine-f1-team-form-partnership/2479181/Shamir Optical Industry and Alpine F1 Team have announced an innovative new partnership that will see Shamir become Alpine F1 Team’s optical performance partner. This collaboration, initiated by
- J&J Vision Announces Collaboration with Menicon to Bring Forward Contact Lenses for Childrenhttps://modernod.com/news/jj-vision-announces-collaboration-with-menicon-to-bring-forward-contact-lenses-for-children/2479057/Johnson & Johnson Vision announced a global strategic collaboration with Menicon, a manufacturer of contact lenses. As part of the collaboration, Menicon will develop and manufacture the contact lenses to help manage the progression of myopia in children. Johnson & Johnson Vision will foc
- Newly Formed Ophthalmology Foundation Will Improve Global Eye Care Through Educationhttps://modernod.com/news/newly-formed-ophthalmology-foundation-will-improve-global-eye-care-through-education/2478972/The newly incorporated nonprofit Ophthalmology Foundation is laying the groundwork to improve global eye care and ophthalmic practice, particularly in low-resource and underserved countries, according to a company news release. Led by a global board of ophthalmologists, ophthalmology professors,
- Biden Picks Former FDA Commissioner David Kessler to Lead Operation Warp Speedhttps://modernod.com/news/biden-picks-former-fda-commissioner-david-kessler-to-lead-operation-warp-speed/2478768/US President-elect Joe Biden announced a number of appointments to the incoming team handling the response to the COVID-19 pandemic, including naming David Kessler as chief science officer. Mr. Kessler, who served as FDA commissioner between 1990 and 1997, will reportedly share oversight of Opera
- AsclepiX Therapeutics Doses First Patient in Phase 1/2a Trial of AXT107 Intravitreal Self-Forming Gel Depot Peptide for DMEhttps://modernod.com/news/asclepix-therapeutics-doses-first-patient-in-phase-1-2a-trial-of-axt107-intravitreal-self-forming-gel-depot-peptide-for-dme/2478717/AsclepiX Therapeutics announced that the first patient has been dosed in the phase 1/2a CONGO clinical trial to evaluate the safety and bioactivity of AXT107 in patients with diabetic macular edema (DME). “Dosing the first patient with AXT107 shortly after the acceptance of its IND is a si